<DOC>
	<DOCNO>NCT01283204</DOCNO>
	<brief_summary>This study evaluate antitumor activity ( i.e . progression free survival , overall survival , response rate , etc ) , safety quality life patient recurrent metastatic gastric cancer 4-regimen ( i.e . SP , FL/Tax , FL/Doc , FOLFOX ) base chemotherapy . In addition , evaluate efficacy adverse event anticancer agent accord result pharmacogenetic study .</brief_summary>
	<brief_title>Trial 4-regimen ( SP , FL/Tax , FL/Doc , FOLFOX ) Patients With Recurrent Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach Unresectable metastatic disease recur AGC Age ≥ 20 year old Eastern Cooperative Oncology Group performance status 02 Estimated life expectancy &gt; 12weeks Patients pretreatment ( radiotherapy , chemotherapy ) carry . ( However , adjuvant chemotherapy use one kind medication allow . It must pass 6 month since end treatment . ) Conventional radiation therapy perform 2 week . And allow radiation therapy primary tumor , measurable lesion , abdominal According RECIST ver.1.1 , use image technique ( CT MRI ) , measurement possible disease measurable , assessable disease Screening laboratory value within follow limit : Hemoglobin ≥ 9 g/dL , Absolute neutrophil count ≥ 1.5 x 10³/L , Platelet count ≥ 75 x 10³/L , Serum creatinine ≤ 1.5 x UNL , Creatinine clearance ≥ 50 mL/min , AST/ALT ≤ 5.0 x UNL The patient protector sign consent form . And able understand right withdraw consent without disadvantage . Prior chemotherapy ( however , previous ( neo ) adjuvant chemotherapy allow finish least 6month ago except S1 , Paclitaxel , Docetaxel , Oxaliplatin . Allowed 5FU , Cisplatin finish 6month ago ) Patients oral intake impossible malabsorption syndrome Patients medically uncontrolled severe complication infection Patients central nervous system disorder , mental disorder , evidence CNS metastases Patient diagnose active overlapping cancer within past 5years except adequately treat carcinoma insitu cervix , basal squamous cell carcinoma skin The possibility ( ) pregnancy , pregnant lactate woman Patients clinically significant heart disease Progression gastric lesion possible evaluate During clinical trial , patient receive systemic chemotherapy clinical trial drug radiotherapy ( However , possible palliative radiotherapy treatment pain relief primary lesion 2 week ) Peripheral neuropathy Grade 2 great . Patients take drug change pharmacological activity S1 medicine ( Warfarin , phenytoin , allopurinol etc. ) . Except regular treatment corticosteroid ( equivalent drug ) . However , allow purpose pretreatment study drug control nausea vomit . ( However , allow treatment acute allergic reaction , treatment low dos ( methylprednisolone 20mg less , equivalent drug ) 6 month ) Other case Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety . Psychological condition dementia would permit subject complete study sign inform consent Patients dropout sure clinical trial regular followup follow reason . For example , psychological , social , family , geographic reason difficult condition compliance clinical trial proper follow . Poorly control chronic liver disease diabetes mellitus Else , investigator 's opinion , exclude patient study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>